The FDA has granted approval for Johnson & Johnson’s Rybrevant (amivantamab-vmjw) in combination with chemotherapy for treating advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations. This approval marks the third new indication for Rybrevant this year, highlighting its potential as a treatment option for patients with advanced NSCLC.
Johnson & Johnson’s Rybrevant, a lung cancer treatment, continues to demonstrate positive results. A new study shows that a prophylactic strategy significantly reduces infusion-related reactions, while long-term data from the MARIPOSA study reinforces Rybrevant’s effectiveness in combination with Lazcluze, improving survival and disease control compared to standard treatment.
